98%
921
2 minutes
20
This research delves into the implications of the RNA binding motif, single stranded interacting protein 2 (RBMS2)-a gene associated with tumor-suppressing functions-in the context of kidney renal clear cell carcinoma (ccRCC). Through meticulous exploration of online databases, we have identified a negative association between RBMS2 expression and adverse clinico-pathological features, such as advanced TNM stage. Furthermore, our findings indicate that RBMS2 acts as a prognostic predictor for clinical outcomes in ccRCC, evidenced by both univariate and multivariate analyses. Cellular assays have corroborated these findings, revealing that an overexpression of RBMS2 curtails ccRCC cell proliferation and migration. Additionally, our research has unearthed links between RBMS2 and immune infiltration within the ccRCC tumor microenvironment. Collectively, our results underscore the tumor-inhibiting role of RBMS2 in ccRCC and spotlight its potential as a prognostic marker and therapeutic intervention target.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697775 | PMC |
http://dx.doi.org/10.1155/2023/5512781 | DOI Listing |
JCI Insight
September 2025
Division of Nephrology, Boston University Chobanian & Avedisian School of Medicine, Boston, United States of America.
Background: Active vitamin D metabolites, including 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), have potent immunomodulatory effects that attenuate acute kidney injury (AKI) in animal models.
Methods: We conducted a phase 2, randomized, double-blind, multiple-dose, 3-arm clinical trial comparing oral calcifediol (25D), calcitriol (1,25D), and placebo among 150 critically ill adult patients at high-risk of moderate-to-severe AKI. The primary endpoint was a hierarchical composite of death, kidney replacement therapy (KRT), and kidney injury (baseline-adjusted mean change in serum creatinine), each assessed within 7 days following enrollment using a rank-based procedure.
JAMA Netw Open
September 2025
Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock.
Importance: Patients with kidney failure (KF) receiving long-term dialysis have increased incidence of atrial fibrillation (AF). Patients with KF and AF have increased risk of stroke, death, and bleeding compared with age-matched cohorts. In KF, the use of oral anticoagulants (OACs) increases hemorrhage risk, offsetting potential benefits and making left atrial appendage occlusion (LAAO) a potentially promising solution for risk reduction in AF.
View Article and Find Full Text PDFJ Nephrol
September 2025
Institute of Nephrology, Madras Medical College, Chennai, India.
Background: IgA nephropathy is a disease with a highly variable natural history, for which there is an increasing understanding of the role of complement activation in its pathogenesis and progression. We aimed to assess the clinical and prognostic implications of C4d staining in the kidney biopsy of IgA nephropathy patients.
Methods: This was a retrospective observational study wherein the medical records of IgA nephropathy patients were reviewed and baseline characteristics, kidney biopsy findings, treatment response and follow-up data were noted.
Int Urol Nephrol
September 2025
Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Purpose: Living donor kidney transplantation is a critical strategy to address the growing burden of end-stage kidney disease (ESKD) in Malaysia. Whilst living donation is generally safe, concerns remain regarding long-term donor outcomes. This study aimed to evaluate renal function and morbidity changes in living kidney donors 1 year post-donation, and to identify predictors of impaired kidney function.
View Article and Find Full Text PDFWorld J Urol
September 2025
Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France.
Purpose: In 5-10% of cases, renal cancer extends into the venous system, particularly the inferior vena cava (IVC), which worsens prognosis. This study aims to assess morbidity, mortality, and oncological outcomes of patients treated surgically for renal cancer with IVC extension over a 30-year period, in two experienced centers.
Materials And Methods: This bicentric, retrospective study analyzed patients treated between 1988 and 2020 for renal cancer involving the IVC.